Compare GLP & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLP | MNKD |
|---|---|---|
| Founded | 2005 | 1991 |
| Country | United States | United States |
| Employees | 4700 | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 793.6M |
| IPO Year | N/A | 2004 |
| Metric | GLP | MNKD |
|---|---|---|
| Price | $47.40 | $2.82 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $46.00 | $8.69 |
| AVG Volume (30 Days) | 30.8K | ★ 3.3M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | $64.13 | $35.81 |
| Revenue Next Year | $11.74 | $11.89 |
| P/E Ratio | ★ $23.28 | $137.75 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $39.58 | $2.23 |
| 52 Week High | $56.51 | $6.51 |
| Indicator | GLP | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 61.40 | 52.60 |
| Support Level | $45.78 | $2.52 |
| Resistance Level | $48.48 | $2.98 |
| Average True Range (ATR) | 1.49 | 0.13 |
| MACD | 0.28 | 0.05 |
| Stochastic Oscillator | 100.00 | 67.06 |
Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the GDSO segment.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.